secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2024-12-06T23:59:59+00:00
Accession:  0001437749-24-036825
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar doses first patient with uPAR-targeted radiopharmaceutical MNPR-101-Lu
------------------------------------------------------------------------------

- First patient dosed under US compassionate use protocol for metastatic pancreatic cancer.
- MNPR-101-Lu targets uPAR; infusion well-tolerated with no serious adverse reactions.
- Patient's tumor showed uPAR expression via prior MNPR-101-Zr PET/CT imaging.
- Two Phase 1 studies ongoing in Australia for MNPR-101-Zr (imaging) and MNPR-101-Lu (treatment).
- Company believes this is the world's first dosing of a uPAR-targeted therapeutic radiopharmaceutical.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924036825/0001437749-24-036825-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924036825/mnpr20241205_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-036825

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer